Corcept Therapeutics - CORT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $32.00
  • Forecasted Upside: 28.10 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$24.98
▲ +0.04 (0.16%)

This chart shows the closing price for CORT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Corcept Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CORT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CORT

Analyst Price Target is $32.00
▲ +28.10% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Corcept Therapeutics in the last 3 months. The average price target is $32.00, with a high forecast of $35.00 and a low forecast of $30.00. The average price target represents a 28.10% upside from the last price of $24.98.

This chart shows the closing price for CORT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Corcept Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/8/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/4/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/3/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2022Truist FinancialDowngradeHoldN/A
8/4/2022HC WainwrightBoost TargetBuy$29.00 ➝ $33.00N/A
8/1/2022Truist FinancialDowngradeBuy ➝ Hold$30.00Low
7/27/2022Jefferies Financial GroupUpgradeHold ➝ Buy$21.00 ➝ $35.00Low
2/16/2022HC WainwrightReiterated RatingBuy$29.00High
2/2/2022Canaccord Genuity GroupInitiated CoverageBuy$30.00Medium
1/28/2022Truist FinancialInitiated CoverageBuy$30.00High
7/30/2021HC WainwrightReiterated RatingBuyMedium
6/23/2021HC WainwrightLower TargetBuy$32.00 ➝ $29.00Low
6/22/2021UBS GroupReiterated RatingPositiveHigh
11/27/2020HC WainwrightBoost TargetPositive ➝ Buy$22.00 ➝ $32.00Low
11/4/2020HC WainwrightBoost TargetBuy$18.00 ➝ $22.00High
8/5/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$16.00High
2/21/2020Cantor FitzgeraldReiterated RatingNeutral$14.00 ➝ $15.00Low
9/24/2019Jefferies Financial GroupInitiated CoverageBuy$20.00Medium
9/6/2019HC WainwrightInitiated CoverageBuy$18.00Low
5/1/2019Cantor FitzgeraldReiterated RatingHold$14.00Low
2/26/2019Cantor FitzgeraldSet TargetHold$14.00High
2/5/2019B. RileySet TargetHold$11.00High
2/1/2019B. RileyDowngradeBuy ➝ Neutral$22.00 ➝ $12.00Low
2/1/2019Cantor FitzgeraldDowngradeOverweight ➝ Neutral$20.00 ➝ $14.00High
12/12/2018Cantor FitzgeraldUpgradeNeutral ➝ Overweight$17.00 ➝ $29.00High
11/19/2018Cantor FitzgeraldSet TargetHold$17.00Medium
11/2/2018Cantor FitzgeraldReiterated RatingHold ➝ Hold$17.00High
10/1/2018Cantor FitzgeraldSet TargetHold$17.00Medium
8/23/2018Cantor FitzgeraldInitiated CoverageNeutral$17.00Medium
8/13/2018B. RileyLower TargetBuy ➝ Buy$30.00 ➝ $22.00High
8/10/2018Stifel NicolausReiterated RatingHold$20.00 ➝ $11.00High
5/31/2018Stifel NicolausDowngradeBuy ➝ Hold$20.00High
3/8/2018B. RileyInitiated CoverageBuy ➝ Buy$30.00Low
2/5/2018Piper Jaffray CompaniesSet TargetBuy$30.00High
2/5/2018Stifel NicolausLower TargetBuy$25.00 ➝ $20.00Low
(Data available from 12/4/2017 forward)

News Sentiment Rating

0.65 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
5/8/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
7/7/2022
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/6/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/5/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/5/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/4/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/4/2022

Current Sentiment

  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Corcept Therapeutics logo
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $24.98
Low: $24.67
High: $25.16

50 Day Range

MA: $26.64
Low: $24.51
High: $29.96

52 Week Range

Now: $24.98
Low: $15.82
High: $30.14

Volume

301,902 shs

Average Volume

509,632 shs

Market Capitalization

$2.69 billion

P/E Ratio

24.98

Dividend Yield

N/A

Beta

0.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Corcept Therapeutics?

The following sell-side analysts have issued research reports on Corcept Therapeutics in the last year: Canaccord Genuity Group Inc., HC Wainwright, Jefferies Financial Group Inc., StockNews.com, and Truist Financial Co..
View the latest analyst ratings for CORT.

What is the current price target for Corcept Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Corcept Therapeutics in the last year. Their average twelve-month price target is $32.00, suggesting a possible upside of 28.1%. Jefferies Financial Group Inc. has the highest price target set, predicting CORT will reach $35.00 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $30.00 for Corcept Therapeutics in the next year.
View the latest price targets for CORT.

What is the current consensus analyst rating for Corcept Therapeutics?

Corcept Therapeutics currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CORT will outperform the market and that investors should add to their positions of Corcept Therapeutics.
View the latest ratings for CORT.

What other companies compete with Corcept Therapeutics?

How do I contact Corcept Therapeutics' investor relations team?

Corcept Therapeutics' physical mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company's listed phone number is (650) 327-3270 and its investor relations email address is [email protected] The official website for Corcept Therapeutics is www.corcept.com. Learn More about contacing Corcept Therapeutics investor relations.